Merck Alliance with CST for PhosphoScan Proteomics Technology
Merck will use Cell Signaling Technology’s PhosphoScan technology to develop biomarker assays for its oncology therapeutics program under an alliance announced this week.
The PhosphoScan technology allows for the discovery of drug target phospho-profiles in cells and disease tissues. CST will also provide Merck its expertise in antibody development and validation to develop high specificity biomarker assays.
Financial terms of the deal were not disclosed.
Biobase Nets €3M Contract to Develop Technology for Disease Analysis
Biobase this week said it has been awarded a three-year, €3 million [$4 million] European Union contract to develop technology to analyze complex disease mechanisms. The project, called Net2Drug, will be coordinated by Biobase and will involve several international participants, the company said in a statement.
Net2Drug will integrate different “omics” databases, such as proteomics and genomics, in cohesive networks “to facilitate comprehensive understanding of complex human pathologies,” said Alexander Kel, senior vice president of R&D for Biobase, in a statement. The goal is to create a “toolbox” integrating bioinformatics, chemoinformatics, and experimental methods to identify potential therapeutic targets.
Based in Wolfenbuttel, Germany, Biobase is a provider of expertly curated biological databases and software tools
Bruker Daltonics Revs Slide 1.1 Percent in 2006
While Bruker Biosciences saw overall revenues rise 17 percent in 2006, revenues generated by the division housing its proteomics instruments declined slightly last year.
The company does not break out financials for its separate divisions during its earnings releases, but according to a document filed recently with the US Securities and Exchange Commission, during full-year 2006, Bruker Daltonics recorded revenues of $159.7 million, down 1.1 percent compared to $161.4 million in revenues in full-year 2005.
In its filing, the company blamed the dropoff to “higher life science system revenues year-over-year, offset by lower sales of CBRN systems during 2006 compared to 2005, lower grant revenue, and lower aftermarket revenues, which includes accessory sales, consumables, training and services.”
CBRN systems are instruments for chemical, biological, radiological, and nuclear detection. Aftermarket revenues for the Daltonics division fell to $28.6 million last year from $30.6 million in 2005.
Total revenues for Bruker Biosciences rose to $435.8 million last year from $372.3 million in full-year 2005.
GeneWorks Distributes Ariadne Products Down Under
Ariadne said this week GeneWorks will distribute its products in Australia and New Zealand. GeneWorks is an Australian supplier of molecular biology research products.
GeneWorks will offer Ariadne’s Pathway Studio “as an essential tool for microarray, proteomics, and other experimental data analysis,” Ariadne said in a statement. GeneWorks will also provide technical and sales support to Pathway Studio users in Australia and New Zealand.
Terms of the company’s distribution agreement were not disclosed.
MDS Closes on Molecular Devices Purchase
MDS today this week it has closed its $615 million acquisition of Molecular Devices.
MDS is merging Molecular Devices with its MDS Sciex business to form a new unit, MDS Analytical Technologies, led by MDS Sciex President Andy Boorn.
Molecular Devices’ stock has been delisted from the Nasdaq Global Select Market.
The two businesses had combined revenues of $432 million last year, and MDS expects Molecular Devices to contribute $190 million in revenue over the coming year. When the deal was announced in January, MDS said that its Sciex business will continue its mass spectrometry partnerships with Applied Biosystems and PerkinElmer.
Applera Declares Dividend on ABI Stock
Applera’s board announced a regular quarterly dividend of $.0425 per share this week on Applied Biosystems common stock, payable on July 2 to stockholders of record as of the close of business on June 1. Applera is the parent company of ABI.